Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Lancaster
S Camarata

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
American Journal of Respiratory and Critical Care Medicine|September 16, 2000
Multiorgan nuclear factor kappa B activation in a transgenic mouse model of systemic inflammationT S Blackwell, F E Yull, C L Chen, et al.
BMJ Open Respiratory Research|August 18, 2018
Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trialsSteven D Nathan, Lisa H Lancaster, Carlo Albera, et al.
International Journal of Radiation Oncology, Biology, Physics|July 14, 2026
Quality of life results of addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy: NRG Oncology/RTOG 0534 SPPORTDeborah W Bruner, Theodore G Karrison, Alan Pollack, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 8, 2017
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosisLisa H Lancaster, Joao A de Andrade, Joseph D Zibrak, et al.
American Journal of Respiratory and Critical Care Medicine|August 9, 2017
A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary FibrosisJoseph M Parker, Ian N Glaspole, Lisa H Lancaster, et al.
Chest|November 26, 2018
Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary FibrosisSteven D Nathan, Ulrich Costabel, Ian Glaspole, et al.
American Journal of Respiratory and Critical Care Medicine|August 16, 2008
Serum inter-alpha-trypsin inhibitor and matrix hyaluronan promote angiogenesis in fibrotic lung injuryStavros Garantziotis, Enrique Zudaire, Carol S Trempus, et al.
Annals of the American Thoracic Society|March 19, 2021
A Phase I Randomized, Controlled, Clinical Trial of Valganciclovir in Idiopathic Pulmonary FibrosisTimothy S Blackwell, Justin C Hewlett, Wendi R Mason, et al.
BMJ Open Respiratory Research|July 7, 2020
Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO RegistryLaurie D Snyder, Christopher Mosher, Colin H Holtze, et al.
American Journal of Respiratory and Critical Care Medicine|April 30, 2019
Patient Registries in Idiopathic Pulmonary FibrosisDaniel A Culver, Jürgen Behr, John A Belperio, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
American Journal of Respiratory and Critical Care Medicine|September 16, 2000
Multiorgan nuclear factor kappa B activation in a transgenic mouse model of systemic inflammationT S Blackwell, F E Yull, C L Chen, et al.
BMJ Open Respiratory Research|August 18, 2018
Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trialsSteven D Nathan, Lisa H Lancaster, Carlo Albera, et al.
International Journal of Radiation Oncology, Biology, Physics|July 14, 2026
Quality of life results of addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy: NRG Oncology/RTOG 0534 SPPORTDeborah W Bruner, Theodore G Karrison, Alan Pollack, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 8, 2017
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosisLisa H Lancaster, Joao A de Andrade, Joseph D Zibrak, et al.
American Journal of Respiratory and Critical Care Medicine|August 9, 2017
A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary FibrosisJoseph M Parker, Ian N Glaspole, Lisa H Lancaster, et al.
Chest|November 26, 2018
Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary FibrosisSteven D Nathan, Ulrich Costabel, Ian Glaspole, et al.
American Journal of Respiratory and Critical Care Medicine|August 16, 2008
Serum inter-alpha-trypsin inhibitor and matrix hyaluronan promote angiogenesis in fibrotic lung injuryStavros Garantziotis, Enrique Zudaire, Carol S Trempus, et al.
Annals of the American Thoracic Society|March 19, 2021
A Phase I Randomized, Controlled, Clinical Trial of Valganciclovir in Idiopathic Pulmonary FibrosisTimothy S Blackwell, Justin C Hewlett, Wendi R Mason, et al.
BMJ Open Respiratory Research|July 7, 2020
Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO RegistryLaurie D Snyder, Christopher Mosher, Colin H Holtze, et al.
American Journal of Respiratory and Critical Care Medicine|April 30, 2019
Patient Registries in Idiopathic Pulmonary FibrosisDaniel A Culver, Jürgen Behr, John A Belperio, et al.
Pageof 7